While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna crushed third-quarter expectations on Thursday and turned around a surprise profit. But Moderna stock pulled back.

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.

2024年11月7日，Moderna公司打破了市场预期，公布了其2024年第三季度财报，收入达到19亿美元，较去年同期增长3.5%。这一业绩的背后，除了组织运营的成功管理，更重要的是其新冠疫苗Spikevax的出色表现。然而，尽管在财报中取得了意外的成功，这份喜悦却伴随着不可忽视的警示和市场竞争的压力。 全球新冠疫苗市场的现状 自COVID-19疫情开始以来，新冠疫苗市场经历了迅猛的发展。在这一领 ...

周四，TD Cowen将Moderna ...